Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 830 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer December 19, 2025 Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study... July 25, 2019 Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... July 9, 2025 Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors July 22, 2022 Load more HOT NEWS Hable con su médico sobre las opciones de cirugía de mama Making Cancer Care More Equitable: A Cancer Survivor’s Story Breast Cancer Patients with Low Breast Density May Be More Likely... TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness...
